

## Oleanolic acid as a potential drug molecule: A review

Manisha H Vite \*, Mayuri I Sonawane and Prathmesh M Vayal

Shivajirao S Jondhle college of Pharmacy, Asangaon, Thane 421601, Maharashtra, India.

World Journal of Advanced Research and Reviews, 2023, 17(01), 249–254

Publication history: Received on 25 November 2022; revised on 05 January 2023; accepted on 07 January 2023

Article DOI: <https://doi.org/10.30574/wjarr.2023.17.1.1469>

### Abstract

**Objective:** Oleanolic acid is traditionally used medicinal remedies in India. Oleanolic acid or oleanic acid is a naturally occurring pentacyclic triterpenoid related to betulinic acid. It is widely distributed in food and plants where it exists as a free acid or as an aglycone of triterpenoid saponins.

**Key findings:** Oleanolic acid is relatively non-toxic, hepatoprotective, and exhibits antitumor and antiviral properties. It was found to exhibit weak anti-HIV and weak anti-HCV activities in vitro, but more potent synthetic analogs are being investigated as potential drugs.

**Conclusion:** This review is an overall overview of the existing pharmacology of Oleanolic acid, helping to fuel further research in the various unexplored activities that are attributable to this plant.

**Keywords:** Oleanolic acid; Hepatoprotective; Antitumor; Antiviral; Antibacterial

### 1. Introduction


*Oleanolic acid* is used for various traditional medicinal remedies in India. Oleanolic acid belongs to the pentacyclic triterpene family. It is widely distributed in food and plants where it exists as a free acid or as an aglycone of triterpenoid saponins<sup>[1,2]</sup>. Oleanolic acid can be found in olive oil, *Phytolacca americana* (American pokeweed), and *Syzygium* spp, garlic, etc. It was first studied and isolated from several plants, including *Olea europaea*<sup>[1,3,4]</sup> (leaves, fruit), *Rosa woodsii* (leaves), *Prosopis glandulosa* (leaves and twigs), *Phoradendron juniperinum* (whole plant), *Syzygium claviflorum* (leaves), *Hyptis capitata* (whole plant), *Mirabilis jalapa*<sup>[5]</sup> and *Ternstroemia gymnanthera* (aerial part). Other *Syzygium* species including java apple (*Syzygium samarangense*) and rose apples contain it. Oleanolic acid is relatively non-toxic, hepatoprotective, and exhibits antitumor and antiviral properties. <sup>[6]</sup>Oleanolic acid was found to exhibit weak anti-HIV<sup>[7]</sup> and weak anti-HCV activities in vitro, but more potent synthetic analogs are being investigated as potential drugs. <sup>[8]</sup>

### 2. Material and methods

Oleanolic acid is a naturally occurring pentacyclic triterpenoid related to betulinic acid.

Chemically *Oleanolic acid* is (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydronicene-4a-carboxylic acid with white appearance having chemical formula C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>. It has molecular weight equivalent to 456.711 g/mol and melting point is > 300 °C (572 °F; 573 K). <sup>[1]</sup>

\* Corresponding author: Manisha H Vite



**Figure 1** Chemical structure of Oleanolic acid. [1]

### 2.1. Biological activities

Oleanolic acid is relatively non-toxic, exhibit antimycotic, antitumoral, antibacterial, hepatoprotective, antiviral, and antiparasitic properties [9-16]. Oleanolic acid was found to exhibit weak anti-HIV and weak anti-HCV activities in vitro, but more potent synthetic analogs are being investigated as potential drugs. An extremely potent synthetic triterpenoid analog of oleanolic acid was found in 2005 that is a powerful inhibitor of cellular inflammatory processes. They work by the induction by IFN- $\gamma$  of inducible nitric oxide synthase (iNOS) and of cyclooxygenase 2 in mouse macrophages. They are extremely potent inducers of the phase 2 response (e.g., elevation of NADH-quinone oxidoreductase and heme oxygenase 1), which is a major protector of cells against oxidative and electrophile stress. [17]

A 2002 study in Wistar rats found that oleanolic acid reduced sperm quality and motility, causing infertility. After withdrawing exposure, male rats regained fertility and successfully impregnated female rats. [18]

## 3. Results and discussion

### 3.1. Role of Oleanolic acid in Antidiabetic

Oleanolic acid and oleanolic acid glycosides have been shown to have glucose-lowering properties in animal models in vivo. In one study, oleanolic acid glycosides purified from plants, but not oleanolic acid itself, decreased serum glucose levels in rats given an oral glucose load. More recent investigations revealed the ability of oleanolic acid to reduce plasma glucose levels in rats and mice. Although the mechanisms by which oleanolic acid reduces glycemia remain poorly understood, several hypotheses have been suggested including effects on reducing gastric emptying, enhancing acetylcholine release that in turn increases insulin release, or reducing insulin resistance. Teodoro et al. have recently demonstrated that oleanolic acid promotes insulin secretion at both basal glucose levels as well as under stimulatory conditions in the pancreatic  $\beta$ -cell line INS-1 832/13 and enhances acute glucose-stimulated insulin secretion in isolated rat islets. In addition to these acute effects, chronic administration of oleanolic acid increases total cellular insulin protein and mRNA levels in the INS-1 cell line. [3,4]

### 3.2. Oleanolic acid as a Molecular Nutrition and Diabetes

Oleanolic acid is a constituent of the leaves of *Olea europaea* and *Viscum album*. Oleanolic acid is used in Chinese medicine for the treatment of liver disorders, such as viral hepatitis, and has been shown to protect mice from various hepatotoxicants that cause oxidative and electrophilic stresses, including carbon tetrachloride, acetaminophen, bromobenzene, and thioacetamide. Oleanolic acid induces expression levels of NRF2 and its target genes in mouse liver, and administration of oleanolic acid exerts hypoglycemic effects in diabetes rodent models. Importantly, synthetic derivatives of oleanolic acid are shown to exert potent NRF2-inducing activity and have been developed as candidates for NRF2-targeting drugs, e.g., bardoxolone (oleanolic triterpenoid 1-[2-cyano-3,12-dioxooleane-1,9(11)-dien-28-oyl] methyl ester), CDDO-Im, and acetylenic tricyclic bis(cyanooneone). Bardoxolone has been tested in the treatment of diabetic nephropathy and has been shown to successfully increase estimated glomerular filtration rate in patients with the nephropathy. Importantly, we found that administration of CDDO-Im protects pancreatic  $\beta$ -cell damage and lower blood glucose levels in db/db diabetes model mice by inducing NRF2. Bardoxolone has also been shown to lower blood glucose levels in the db/db mice. These findings unequivocally demonstrate that NRF2 retains activity to lower blood glucose levels. [8]

### 3.3. Activity of Oleanolic acid in Health and Disease Prevention

Among olive and pomace oleanolic acid has been the most widely studied and distributed in the vegetable kingdom. In fact, a wide range of biological activities has been attributed to this triterpenoid. Nevertheless, there are not many

studies focused on the cardiovascular properties ascribed to oleanolic acid and structure-related triterpenoids such as erythrodiol. Accordingly, parenteral administration of this triterpenic acid lowers blood pressure in salt-sensitive rats, an effect mainly associated with antioxidative actions. In addition, it has been recently reported that ingestion of pomace olive oil with a high proportion of oleanolic acid and erythrodiol offers a delay in the progression of lipid peroxidation in rat liver microsomes. Despite these recent findings, the effects of oleanolic acid and pomace olive oil on vascular and endothelial function have remained unknown until now. This chapter summarizes the recent and

novel advances in the vasoprotective profile provided by olive and pomace olive oil and their triterpenoids in terms of vasodilatation. [8]

### 3.4. Role of Oleanolic acid in Neurological Autoimmune Diseases

It was reported that treatment with either oleanolic acid or erythrodiol (50 mg/kg), before or at the early phase of EAE, ameliorated neurological signs. Moreover, oleanolic acid treatment decreased the levels of anti-MOG antibodies, blood-brain barrier leakage, and infiltration of inflammatory cells within the CNS. In line with these findings, oral administration of 80 mg/kg of olive leaf extract in rats with EAE reduced behavioral deficits, cellularity of the draining lymph nodes, and production of interferon- $\gamma$  and interleukin-17. It was also reported that celastrol (1 mg/kg/day) ameliorated the behavioral deficits and inhibited the relapse in rats with EAE.

Oleanolic acid had beneficial effects in clinical trials on chronic kidney disease, diabetes mellitus type 2, and some inflammatory conditions such as arthritis. There are about 500 registered clinical trials regarding the therapeutic effects of olive. However, none of them are related to patients with MS. Similarly, no clinical trial has been performed for oleanolic acid, erythrodiol, or celastrol on patients with MS. [6]

### 3.5. Antibacterial Properties of Oleanolic Acids

The antibacterial properties of Oleanolic acid were assayed against different bacterial species, and the obtained results suggested the importance of these compounds as antibiotic drugs. Oleanolic acid inhibited the synthesis of insoluble glucan, catalyzed by crude glucosyltransferase (GTase) from cariogenic *Streptococcus mutans*. [19]. When used against *Mycobacterium tuberculosis*, it was found that Oleanolic acid isolated from *Lantana hispida* was also effective at displaying a MIC value of 25  $\mu\text{g}/\text{mL}$ . [20]. In addition, a MIC of 50  $\mu\text{g}/\text{mL}$  was reported when Oleanolic acid was used against *M. tuberculosis* streptomycin-, isoniazid-, rifampin-, and ethambutol-resistant strains. Similar to Oleanolic acid purified from *Chamaedorea tepejilote* leaves was capable of eliminating *M. tuberculosis* at 100  $\mu\text{g}/\text{mL}$ . [21], suggesting that there is a potential for both compounds to kill this pathogen.

The diversity of the antibacterial properties of Oleanolic acid has also been illustrated against other human bacterial pathogens, such as *S. pneumonia* (MIC of 16  $\mu\text{g}/\text{mL}$ ), methicillin-sensitive and methicillin-resistant *Staphylococcus aureus* (MIC of 8  $\mu\text{g}/\text{mL}$  and 64  $\mu\text{g}/\text{mL}$ , resp.) [22], *Bacillus subtilis* (MIC of 8  $\mu\text{g}/\text{mL}$ ), *B. cereus*, *Enterococcus faecalis* (MIC of 6.25–8.00  $\mu\text{g}/\text{mL}$ ), *E. faecium* (MIC of 8  $\mu\text{g}/\text{mL}$ ), and *Pseudomonas aeruginosa* (MIC of 256  $\mu\text{g}/\text{mL}$ ) [23–24].

### 3.6. Antiviral Properties of Oleanolic Acids

The antiviral properties of Oleanolic acid have been studied since the 1990s; specifically, those used against human immunodeficiency virus (HIV) and the hepatitis virus. HIV belongs to the Retroviridae family and the genus, Lentivirus, which produces characteristically slow and progressive infection [25]. One of the first works [26] dealing with this subject showed that Oleanolic acid purified from *Cynomorium songaricum* (Cynomoriaceae) inhibited HIV-1 protease in a dose-dependent manner (inhibitory concentration [IC]<sub>50</sub> of 8  $\mu\text{g}/\text{mL}$ ). Oleanolic acid and its derivatives were also capable of inhibiting HIV-1 protease, with an IC<sub>50</sub> of 4–20  $\mu\text{g}/\text{mL}$ . [27]. The inhibition of this enzyme produces immature and noninfectious virions and molecules, consequently blocking the life cycle of HIV [28]; this will ultimately improve the patient's quality of life. In addition, ex vivo experiments showed that peripheral blood mononuclear cells (PBMC) from HIV-infected patients, which were incubated with different doses of Oleanolic acid, presented significant reduction of viral replication, which was comparable with the drug, azidothymidine (AZT). Similar results were found when PBMC from healthy donors were infected with HIV-1, yielding an effective concentration (EC)<sub>50</sub> of 22.7  $\mu\text{M}$  and 24.6  $\mu\text{M}$ , respectively [29]. Moreover, [30] demonstrated that Oleanolic acid could eliminate, with high selectivity, HIV (therapeutic index [TI] ratio of 12.8) when compared to the H9 cell lineage; however, the AZT drug presented with the highest TI, which was 41.667.

### 3.7. The Antiprotozoal Properties of Oleanolic acid

Oleanolic acid also displayed appreciable antiparasitic effects against *Plasmodium falciparum*, *Toxoplasma gondii*, *Trypanosoma cruzi*, and *Leishmania* sp.

The parasitic disease with the greatest impact is malaria; it affects around 40% of the world's population, spanning across more than 100 countries, and its etiological agent is a protozoa belonging to the genus, *Plasmodium* [31]. Although different drugs can eliminate this parasite, the problem with the *Plasmodium* sp. is that its resistance needs to be overcome [32]; this indicates that the search for new antimalarial compounds is necessary and urgent.

In this regard, one of the first works to demonstrate the antimalarial properties of triterpenes against chloroquine-resistant and chloroquine-sensitive *Plasmodium falciparum* was conducted by Steele et al. [33]. Other studies have also demonstrated that Oleanolic acid purified from *Satureia parvifolia*, *Mimusops caffra*, *M. obtusifolia*, and *Kleinia odora* were able to eliminate *P. falciparum*. [34–36]

Tan et al. [37] evaluated the leishmanicidal potential of Oleanolic acid extracted from *Salvia cilicica* roots. The obtained results showed that Oleanolic acid was primarily active against intracellular amastigote forms of *L. donovani* and *L. major*, with an  $IC_{50}$  of 12.7 nM and 7.0 nM, respectively.

Recently, a bioguided study conducted with extracts of *Baccharis uncinella* leaves led to the identification of a bioactive fraction that contained Oleanolic acid triterpenes. This fraction showed moderated activity against *L. (V.) braziliensis* and *L. (L.) amazonensis* promastigotes, [11]

---

## 4. Conclusion

Conclusively, oleanolic acid is an efficient drug molecule with a potential to act against different diseases. It has widespread biological activities such as hepatoprotective, antidiabetic, viral hepatitis, hepatotoxicants, and antioxidant, anticancer and in early phase of EAE. Thus, oleanolic acid can be considered as potential drug molecule as well as adjuvant for various biological implications and thereby serving the human society.

---

## Compliance with ethical standards

### *Disclosure of conflict of interest*

No conflict of interest.

---

## References

- [1] Oleanolic Acid - an overview | ScienceDirect Topics
- [2] Hill R. A. and Connolly J. D., "Triterpenoids," *Natural Product Reports*, 2012, vol. 29 (7), 780–818.
- [3] Simonsen J. L. and Ross W. C. J., "Hydroxy acids, hydroxy lactones, hydroxyaldehyde acids, hydroxyketo acids and the stereochemistry of the triterpenes," in *The Terpenes: The Triterpenes and Their Derivatives*, Cambridge University Press, Cambridge, UK, 1957.
- [4] Sporn M. B., Liby K. T., Yore M. M., L. Fu, Lopchuk J. M., and Gribble G. W., "New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress," *Journal of Natural Products*, 2011, vol. 74(3), 537–545.
- [5] Siddiqui S., Siddiqui B.S., Adil Q. and Begum S., *Constituents of Mirabilis Jalapa Fitoterapia*, 1990, Vol. 61(5), 471.
- [6] Liu J "Pharmacology of oleanolic acid and ursolic acid". *J Ethnopharmacol.*1995, vol. 49 (2):.57–68.
- [7] Mengoni F, Lichtner M, Battinelli L, Marzi M, Mastroianni CM, Vullo V, Mazzanti G (February 2002). "In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells". *Planta Med.* 2003, Vol.68 (2):111–4.
- [8] Yu F, Wang Q, Zhang Z, Peng Y, Qiu Y, Shi Y, et al. (June 2013). "Development of oleanane-type triterpenes as a new class of HCV entry inhibitors". *J. Med. Chem.*, 2007, Vol.56 (11): 4300–19.
- [9] Patlolla J. M. R. and Rao C. V., "Triterpenoids for cancer prevention and treatment: current status and future prospects," *Current Pharmaceutical Biotechnology*, 2012, vol. 13(1), 147–155.

- [10] Bonaccorsi I, F. Altieri, I. Sciamanna et al., “Endogenous reverse transcriptase as a mediator of ursolic acid's anti-proliferative and differentiating effects in human cancer cell lines,” *Cancer Letters*, 2008, vol. 263(1), 130–139.
- [11] Passero L. F. D., Bonfim-Melo A., Corbett C. E. P. et al., “Anti-leishmanial effects of purified compounds from aerial parts of *Baccharis uncinella* CDC (Asteraceae),” *Parasitology Research*, 2011, vol. 108(3), 529–536.
- [12] Chinou I., Liolios C. H., Moreau D., and Roussakis C. H., “Cytotoxic activity of *Origanum dictamnus*,” *Fitoterapia*, 2007, vol. 78(5), 342–344.
- [13] Cunha W. R., Martins C., D. Ferreira D. S., Crotti A. E. M., Lopes N. P., and Albuquerque S., “In Vitro trypanocidal activity of triterpenes from *Miconia* species,” *Planta Medica*, 2003, vol. 69(5), 470–472.
- [14] Taketa A. T. C., Gnoatto S. C. B., Gosmann G., Pires V. S., Schenkel E. P., and D. Guillaume, “Triterpenoids from Brazilian *Ilex* species and their in vitro antitrypanosomal activity,” *Journal of Natural Products*, 2004, vol. 67(10), 1697–1700.
- [15] Traore-Keita F., Gasquet M., Giorgio C. di et al., “Antimalarial activity of four plants used in traditional medicine in Mali,” *Phytotherapy Research*, 2000, vol. 14(1), 45–47.
- [16] Torres-Santos E. C., Lopes D., Oliveira R. R. et al., “Antileishmanial activity of isolated triterpenoids from *Pourouma guianensis*,” *Phytomedicine*, 2004, vol. 11(2) 114–120.
- [17] Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, et al. (March 2005).
- [18] Mdhului MC, van der Horst G (October 2002). "The effect of oleanolic acid on sperm motion characteristics and fertility of male Wistar rats". *Lab. Anim.* 2007, Vol.36 (4) 432–7.
- [19] Kozai K., Miyake Y., Kohda H. et al., “Inhibition of glucosyltransferase from *Streptococcus mutans* by oleanolic acid and ursolic acid,” *Caries Research*, 1987, vol. 21(2), 104–108.
- [20] Jiménez-Arellanes A., Meckes M., Torres J., and Luna-Herrera J., “Antimycobacterial triterpenoids from *Lantana hispidula* (Verbenaceae),” *Journal of Ethnopharmacology*, 2007, vol. 111(2), 202–205.
- [21] Jiménez A., Meckes M., Alvarez V., Torres J., and Parra R., “Secondary metabolites from *Chamaedora tepejilote* (Palmae) are active against *Mycobacterium tuberculosis*,” *Phytotherapy Research*, 2005, vol. 19(4), 320–322.
- [22] Woldemichael G. M., Franzblau S. G., Zhang F., Wang Y., and Timmermann B. N., “Inhibitory effect of sterols from *Ruprechtia triflora* and diterpenes from *Calceolaria pinnifolia* on the growth of *Mycobacterium tuberculosis*,” *Planta Medica*, 2003, vol. 69(7), 628–631.
- [23] Horiuchi K., Shiota S., Hatano T., Yoshida T., Kuroda T., and Tsuchiya T., “Antimicrobial activity of oleanolic acid from *Salvia officinalis* and related compounds on vancomycin-resistant enterococci (VRE),” *Biological & Pharmaceutical Bulletin*, 2007, vol. 30(6), 1147–1149.
- [24] Cunha W. R., de Matos G. X., Souza M. G. M et al., “Evaluation of the antibacterial activity of the methylene chloride extract of *Miconia ligustroides*, isolated triterpene acids, and ursolic acid derivatives,” *Pharmaceutical Biology*, 2010, vol. 48(2), 166–169.
- [25] Girard M. P., Osmanov S., Assossou O. M., and Kieny M.P. “Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review,” *Vaccine*, 2011, vol. 29(37), 6191–6218.
- [26] Nakamura C. Ma, N., Miyashiro H., M. Hattori, and K. Shimotohno, “Inhibitory effects of constituents from *Cynomorium songaricum* and related triterpene derivatives on HIV-1 protease,” *Chemical and Pharmaceutical Bulletin*, 1999, vol. 47(2), 141–145.
- [27] Nakamura N., “Inhibitory effects of some traditional medicines on proliferation of HIV-1 and its protease,” *Yakugaku Zasshi*, 2004, vol. 124(8), 519–529.
- [28] Filho J. R., Falcão H. D. S., Batista L. M., Filho J. M. B., and Piuvezam M. R., “Effects of plant extracts on HIV-1 protease,” *Current HIV Research*, 2010, vol. 8(7), 531–544.
- [29] Mengoni F., Lichtner M., Battinelli L. et al., “In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells,” *Planta Medica*, 2002, vol. 68(2), 111–114.
- [30] Kashiwada Y., Wang H. K., Nagao T. et al., “Anti-AIDS agents—anti-HIV activity of pomolic and structurally related triterpenoids,” *Journal Natural Products*, 1998, vol. 61(9), 1090–1095.

- [31] Oliveira-Ferreira J., Lacerda M. V. G., Brasil P., J. L. B. Ladislau, P. L. Tauil, and C. T. Daniel-Ribeiro, “Malaria in Brazil: an overview,” *Malaria Journal*, 2010, vol. 9(1), article 115.
- [32] Sibley C. H. and Price R. N., “Monitoring antimalarial drug resistance: applying lessons learned from the past in a fast-moving present,” *International Journal for Parasitology: Drugs and Drug Resistance*, 2012, vol. 2, 126–133.
- [33] Steele J. C. P., Warhurst D. C., Kirby G. C., and M. Simmonds S. J., “In vitro and in vivo evaluation of betulinic acid as an antimalarial,” *Phytotherapy Research*, 1999, vol. 13(2), 115–119.
- [34] Baren C. van, Anao I., Lira P. D. L. et al., “Triterpenic acids and flavonoids from *Satureja parvifolia*, evaluation of their antiprotozoal activity,” *Journal of Biosciences*, 2006, vol. 61(3), 189–192.
- [35] Simelane M. B. C., Shonhai A., Shode F. O., Smith P., Singh M., and Opoku A. R., “Anti-plasmodial activity of some zulu medicinal plants and of some triterpenes isolated from them,” *Molecules*, 2013, vol. 18(10), 12313–12323.
- [36] Musayeb N. M. Al, Mothana R. A., El Gamal A. A., Al-Massarani S. M., and Maes L., “In Vitro antiprotozoal activity of triterpenoid constituents of *Kleinhovia odorata* growing in Saudi Arabia,” *Molecules*, 2013, vol. 18(8), 9207–9218.
- [37] Tan N., Kaloga M., Radtke O. A. et al., “Abietane diterpenoids and triterpenoic acids from *Salvia cilicica* and their antileishmanial activities,” *Phytochemistry*, 2002, vol. 61(8), 881–884